

CHEMICAL CONSTITUENTS, COMPUTATIONAL  
STUDIES AND BIOACTIVITIES OF FOUR  
*Knema* SPECIES (MYRISTICACEAE)

ABUBAKAR SIDDIQ SALIHU

UNIVERSITI PENDIDIKAN SULTAN IDRIS

2025

CHEMICAL CONSTITUENTS, COMPUTATIONAL STUDIES AND  
BIOACTIVITIES OF FOUR *Knema* SPECIES (MYRISTICACEAE)

ABUBAKAR SIDDIQ SALIHU

THESIS PRESENTED TO QUALIFY FOR A  
DOCTOR OF PHILOSOPHY

FACULTY OF SCIENCE AND MATHEMATICS  
UNIVERSITI PENDIDIKAN SULTAN IDRIS

2025





**INSTITUT PENGAJIAN SISWAZAH /  
INSTITUTE OF GRADUATE STUDIES**

**BORANG PENGESAHAN PENYERAHAN TESIS/DISERTASI/LAPORAN KERTAS PROJEK  
DECLARATION OF THESIS/DISSERTATION/PROJECT PAPER FORM**

Tajuk / Title: CHEMICAL CONSTITUENTS, COMPUTATIONAL STUDIES AND  
BIOACTIVITIES OF FOUR Knema SPECIES (MYRISTICACEAE)

No. Matrik /Matric's No.: P20221000209

Saya / I : ABUBAKAR SIDDIQ SALIHU

(Nama pelajar / Student's Name)

mengaku membenarkan Tesis/Disertasi/Laporan Kertas Projek (Kedoktoran/Sarjana)\* ini disimpan di Universiti Pendidikan Sultan Idris (Perpustakaan Tuanku Bainun) dengan syarat-syarat kegunaan seperti berikut:-

*acknowledged that Universiti Pendidikan Sultan Idris (Tuanku Bainun Library) reserves the right as follows:-*

1. Tesis/Disertasi/Laporan Kertas Projek ini adalah hak milik UPSI.  
*The thesis is the property of Universiti Pendidikan Sultan Idris*
2. Perpustakaan Tuanku Bainun dibenarkan membuat salinan untuk tujuan rujukan dan penyelidikan.  
*Tuanku Bainun Library has the right to make copies for the purpose of reference and research.*
3. Perpustakaan dibenarkan membuat salinan Tesis/Disertasi ini sebagai bahan pertukaran antara Institusi Pengajian Tinggi.  
*The Library has the right to make copies of the thesis for academic exchange.*
4. Sila tandakan ( ✓ ) bagi pilihan kategori di bawah / Please tick ( ✓ ) for category below:-

**SULIT/CONFIDENTIAL**

Mengandungi maklumat yang berdarjah keselamatan atau kepentingan Malaysia seperti yang termaktub dalam Akta Rahsia Rasmi 1972. / Contains confidential information under the Official Secret Act 1972

**TERHAD/RESTRICTED**

Mengandungi maklumat terhad yang telah ditentukan oleh organisasi/badan di mana penyelidikan ini dijalankan. / Contains restricted information as specified by the organization where research was done.

**TIDAK TERHAD / OPEN ACCESS**

(Tandatangan Pelajar/ Signature)

PROF. MADYA DR. WAN MOHD NUZUL HAKIMI W. SALLEH  
Jabatan Kimia, Fakulti Sains dan Matematik  
Universiti Pendidikan Sultan Idris  
Tanjong Malim, Perak

(Tandatangan Penyelia / Signature of Supervisor)  
& (Nama & Cop Rasmi / Name & Official Stamp)

Tarikh: 9 SEPTEMBER 2025

Catatan: Jika Tesis/Disertasi ini **SULIT @ TERHAD**, sila lampirkan surat daripada pihak berkuasa/organisasi berkenaan dengan menyatakan sekali sebab dan tempoh laporan ini perlu dikelaskan sebagai **SULIT** dan **TERHAD**.

Notes: If the thesis is **CONFIDENTIAL** or **RESTRICTED**, please attach with the letter from the organization with period and reasons for confidentiality or restriction.

## ACKNOWLEDGEMENT

In the name of Allah, the Most Gracious, the Most Merciful. All praise and thanks to Allah (SWT), who has granted me life, strength, patience, and the opportunity to successfully complete this research journey. Without His divine guidance and blessings, none of this would have been possible. First and foremost, I wish to express my deepest and sincere gratitude to my supervisor, Associate Professor Dr. Wan Mohd Nuzul Hakimi W Salleh, who has been far more than a supervisor to me; a mentor, a guardian, and a true source of inspiration. His continuous support, valuable advice, patience, motivation, and immense knowledge have shaped me not only academically but also personally. I am truly blessed and honored to have worked under his supervision. I am also sincerely grateful to all the technical and non-technical staff of the Department of Chemistry, Faculty of Science and Mathematics, Universiti Pendidikan Sultan Idris (UPSI), for their assistance and support throughout my study. My special appreciation goes to Puan Johana binti Johari for her kindness throughout the development of this research. To my beloved Lab 7 family; Faezatul Alwani binti Mohd Rahim, Nur Nabila Mohd Zaini, Nik Nur Asyiqin Nik Mohammed Ainul, Ursula Jane Rezod, Michael Drick Anak Ngalang, and Keith Kathrinna Adward. I am truly blessed to have shared this journey with such amazing and supportive colleagues. Your friendship, teamwork, laughter, and moments we shared in the lab made this challenging journey more meaningful and memorable. I would like to sincerely acknowledge the Malaysian Government and the Ministry of Higher Education Malaysia for granting me the Malaysian International Scholarship (MIS), a great support that came at a crucial point in my academic journey, enabling me to successfully pursue and complete my postgraduate studies in Malaysia. Last but certainly not least, my deepest appreciation and heartfelt love go to my wonderful parents; Prof. Salihu Lawal, Mal. Habiba Haruna, Mal. Zainab Ibrahim, and Mal. Asiya Abdulqadir, for their endless love, prayers, moral support, and sacrifices. Their unwavering belief in me has been the driving force behind my success. To my lovely siblings, thank you for your patience, care, and constant encouragement during the difficult times of this academic journey. May Allah (SWT) bless all of you abundantly and reward you for your kindness, love, and support.

## ABSTRACT

The purpose of this study was to investigate essential oils content, phytochemicals, computational modelling and bioactivities of four *Knema* species (Myristicaceae). Essential oils were extracted *via* hydrodistillation and were analyzed using gas chromatography (GC) and gas chromatography-mass spectrometry (GC-MS). Phytochemicals were isolated using silica gel column chromatography and their chemical structures were elucidated *via* spectroscopic methods including nuclear magnetic resonance, infrared spectroscopy, mass spectrometry, and ultraviolet-visible spectroscopy. Computational studies were performed to assess the binding of isolated compounds to acetylcholinesterase (AChE) and 5-lipoxygenase (5-LOX), and their antibiofilm activities. The major components of the four *Knema* essential oils were as following: *K. intermedia* ( $\tau$ -muurolol, 20.1%), *K. malayana* ( $\delta$ -cadinene, 20.2%), *K. hookeriana* ( $\beta$ -caryophyllene, 26.2%), and *K. furfuracea* (bicyclogermacrene, 23.1%). Phytochemical investigation led to isolation of a new compound (intermedianin) from *K. intermedia* and 22 known compounds including five from *K. intermedia* (cubebin, cubebin acetate, bicubebin B, apigenin, and kaempferol), six from *K. malayana* (3',4',5,7-tetramethoxyflavone, 3',4',5',5,7-pentamethoxyflavone, 4'-hydroxy-3',5',5,7-tetramethoxyflavone, 3-hydroxy-3',4',5',5,7-pentamethoxyflavone, 3,3',5',5,7-pentamethoxyflavone, and stigmasterol), seven from *K. hookeriana* (aptosimon, cubebin acetate, bicubebin A, 5,7-dimethoxyflavone, 4',5,7-trimethoxyflavone, luteolin, and epicatechin), and four from *K. furfuracea* (cubebin, cubebin acetate, bicubebin A, and stigmasterol). Molecular docking studies revealed that intermedianin and aptosimon strongly bind AChE ( $-11.7$  and  $-12.0$  kcal/mol). Aptosimon showed strong binding affinity to 5-LOX ( $-10.1$  kcal/mol) and intermedianin displayed binding to fungal cytochrome enzyme (CYP51B) ( $-11.0$  kcal/mol). Bioactivity studies showed that 3',4',5',5,7-pentamethoxyflavone gave strongest AChE inhibition ( $IC_{50}$  10.2  $\mu$ M), while bicubebin A was the most active against 5-LOX ( $IC_{50}$  15.9  $\mu$ M), and intermedianin was the strongest inhibitor of *Candida albicans* biofilm (22.8%). In conclusion, the current study demonstrated that the essential oils and isolated compounds of the four *Knema* species exhibited strong AChE, 5-LOX, and fungal biofilm inhibitory activities. These findings suggest that the *Knema* species have potential as alternative treatments for brain disorders, inflammation, and fungal infections.

## KANDUNGAN KIMIA, KAJIAN KOMPUTASIONAL DAN BIOAKTIVITI EMPAT SPESIES *Knema* (MYRISTICACEAE)

### ABSTRAK

Tujuan kajian ini adalah untuk menyiasat kandungan minyak pati, fitokimia, model komputasional dan bioaktiviti empat spesies *Knema* (Myristicaceae). Minyak pati diekstrak melalui penyulingan hidro dan dianalisis menggunakan kromatografi gas (GC) dan kromatografi gas-spektrometri jisim (GC-MS). Fitokimia telah dipencilkan menggunakan teknik kromatografi turus silika gel dan struktur kimianya ditentukan melalui kaedah spektroskopi termasuk resonans magnetik nuklear, spektroskopi inframerah, spektrometri jisim dan spektroskopi ultra-lembayung nampak. Kajian komputasional dijalankan untuk mengenalpasti ikatan sebatian yang dipencilkan kepada asetilkolinesteras dan anti-radang, dan aktiviti antibiofilemnya. Komponen utama dalam minyak pati oleh empat spesies *Knema* adalah seperti berikut: *K. intermedia* ( $\tau$ -murolol, 20.1%), *K. malayana* ( $\delta$ -kadinen, 20.2%), *K. hookeriana* ( $\beta$ -karyofailin, 26.2%), dan *K. furfuracea* (bisiklogermakrena, 23.1%). Penyiasatan fitokimia membawa kepada pemencilan satu sebatian baharu daripada *K. intermedia* (intermedianin) dan 22 sebatian termasuk lima daripada *K. intermedia* (kubebin, kubebin asetat, bikubebin B, apigenin, dan kemferol), enam daripada *K. malayana* (3',4',5,7-tetrametoksiflavin, 3',4',5',5,7-pentametoksiflavin, 4'-hidroksi-3',5',5,7-tetrametoksiflavin, 3-hidroksi-3',4',5',5,7-pentametoksiflavin, 3,3',5',5,7-pentametoksiflavin, dan stigmasterol), tujuh daripada *K. hookeriana* (aptosimon, kubebin asetat, bikubebin A, 5,7-dimetoksiflavin, 4',5,7-trimetoksiflavin, luteolin, dan epikatekin), dan empat daripada *K. furfuracea* (kubebin, kubebin asetat, bikubebin A, dan stigmasterol). Kajian padanan molekul mendedahkan bahawa intermedianin dan aptosimon mengikat kuat AChE (-11.7 dan -12.0 kcal/mol). Aptosimon menunjukkan kecenderungan ikatan kuat terhadap 5-LOX (-10.1 kcal/mol) dan intermedianin mempamerkan ikatan terhadap enzim sitokrom fungsi (-11.0 kcal/mol). Kajian bioaktiviti menunjukkan 3',4',5',5,7-pentametoksiflavin memberikan perencatan terkuat AChE (IC<sub>50</sub> 10.2  $\mu$ M), sementara bikubebin A paling aktif terhadap 5-LOX (IC<sub>50</sub> 15.9  $\mu$ M), dan intermedianin adalah perencat terkuat terhadap biofilem *Candida albicans* (22.8%). Kesimpulannya, kajian terkini menunjukkan minyak pati dan sebatian yang dipencilkan oleh empat spesies *Knema* mempamerkan aktiviti kuat AChE, 5-LOX, dan perencatan biofilem fungsi. Penemuan ini mencadangkan bahawa spesies *Knema* berpotensi sebagai rawatan alternatif untuk gangguan otak, keradangan, dan jangkitan fungsi.

## CONTENTS

	<b>Page</b>
<b>DECLARATION OF ORIGINAL WORK</b>	ii
<b>DECLARATION OF DISSERTATION</b>	iii
<b>ACKNOWLEDGEMENT</b>	iv
<b>ABSTRACT</b>	v
<b>ABSTRAK</b>	vi
<b>CONTENTS</b>	vii
<b>LIST OF TABLES</b>	xii
<b>LIST OF FIGURES</b>	xiv
<b>LIST OF SCHEMES</b>	xxi
<b>LIST OF ABBREVIATIONS</b>	xxii
<b>CHAPTER 1 INTRODUCTION</b>	1
1.1 General Introduction	1
1.2 Problem Statement	5
1.3 Objectives of Study	6
1.4 Scopes of Study	7
1.5 Significance of Study	8
<b>CHAPTER 2 LITERATURE REVIEW</b>	10
2.1 Myristicaceae Family	10
2.2 Genus <i>Knema</i>	13
2.2.1 <i>Knema intermedia</i> Warb.	17

2.2.2	<i>Knema malayana</i> Warb.	18
2.2.3	<i>Knema hookeriana</i> Warb.	19
2.2.4	<i>Knema furfuracea</i> Warb.	20
2.3	Introduction to Essential Oils	21
2.4	Essential Oil Studies of the Genus <i>Knema</i>	24
2.5	Phytochemical Studies of the Genus <i>Knema</i>	28
2.5.1	Flavonoids	29
2.5.2	Phenolics	38
2.5.3	Anacardic Acids	44
2.5.4	Acetophenones	47
2.5.5	Miscellaneous Phytochemicals	49
2.6	Biological Activities of the Genus <i>Knema</i>	54
2.6.1	Bioactivities of <i>Knema</i> Essential Oils	54
2.6.2	Bioactivities of <i>Knema</i> Extracts	55
2.6.3	Bioactivities of <i>Knema</i> Phytochemicals	57
2.7	Computational Studies	67
<b>CHAPTER 3 EXPERIMENTAL</b>		75
3.1	Plant Materials	75
3.2	Extraction and Analysis of <i>Knema</i> Essential Oils	76
3.3	Extraction and Analysis of <i>Knema</i> Phytochemicals	79
3.4	Isolation and Purification of <i>Knema</i> Phytochemicals	81
3.4.1	Isolation and Purification of Phytochemicals from <i>K. intermedia</i>	81
3.4.2	Isolation and Purification of Phytochemicals from <i>K. malayana</i>	84

3.4.3	Isolation and Purification of Phytochemicals from <i>K. hookeriana</i>	86
3.4.4	Isolation and Purification of Phytochemicals from <i>K. furfuracea</i>	88
3.5	Spectral Data of Isolated Phytochemicals	89
3.6	Computational Studies	107
3.7	Biological Activities	111
3.7.1	Acetylcholinesterase Activity	111
3.7.2	Anti-inflammatory Activity	112
3.7.3	Antibiofilm Activity	113
<b>CHAPTER 4 RESULTS AND DISCUSSION</b>		115
4.1	Extraction of <i>Knema</i> Essential Oils	115
4.2	Analysis of <i>Knema</i> Essential Oils	116
4.2.1	Chemical Composition of <i>K. intermedia</i> Essential Oil	116
4.2.2	Chemical Composition of <i>K. malayana</i> Essential Oil	119
4.2.3	Chemical Composition of <i>K. hookeriana</i> Essential Oil	123
4.2.4	Chemical Composition of <i>K. furfuracea</i> Essential Oil	126
4.3	Comparative Analysis of <i>Knema</i> Essential Oils	129
4.4	Multivariate Statistical Analysis	135
4.4.1	PCA Analysis	135
4.4.2	HCA Analysis	138
4.5	Phytochemical Studies of <i>K. intermedia</i>	141
4.5.1	Intermedianin (158)	141

4.5.2	Cubebin (159)	152
4.5.3	Cubebin Acetate (160)	158
4.5.4	Bicubebin B (161)	164
4.5.5	Apigenin (162)	171
4.5.6	Kaempferol (163)	179
4.6	Phytochemical Studies of <i>K. malayana</i>	186
4.6.1	3',4',5,7-Tetramethoxyflavone (164)	186
4.6.2	3',4',5',5,7-Pentamethoxyflavone (165)	194
4.6.3	4'-Hydroxy-3',5',5,7-tetramethoxyflavone (166)	199
4.6.4	3-Hydroxy-3',4',5',5,7-pentamethoxyflavone (167)	206
4.6.5	3,3',5',5,7-Pentamethoxyflavone (168)	213
4.6.6	Stigmasterol (169)	220
4.7	Phytochemical Studies of <i>K. hookeriana</i>	226
4.7.1	Aptosimon (170)	226
4.7.2	Cubebin Acetate (160)	236
4.7.3	Bicubebin A (171)	236
4.7.4	5,7-Dimethoxyflavone (172)	244
4.7.5	4',5,7-Trimethoxyflavone (173)	251
4.7.6	Luteolin (174)	256
4.7.7	Epicatechin (175)	265
4.8	Phytochemical Studies of <i>K. furfuracea</i>	274
4.8.1	Cubebin (157)	274
4.8.2	Cubebin Acetate (160)	274

4.8.3	Bicubebin A (171)	275
4.8.4	Stigmasterol (169)	275
4.9	Computational Studies	276
4.9.1	Molecular Docking Studies of Phytochemicals against Acetylcholinesterase	278
4.9.2	Molecular Docking Studies of Phytochemicals against Lipoxygenase	284
4.9.3	Molecular Docking Studies of Phytochemicals against Biofilm	288
4.9.4	ADMET and Drug-Likeness	292
4.9.5	Toxicity Studies of Phytochemicals Using Toxometris-ADMET-Suite	300
4.10	Biological Activities	303
4.10.1	Acetylcholinesterase Activity	303
4.10.2	Anti-inflammatory Activity	311
4.10.3	Antibiofilm Activity	317
<b>CHAPTER 5</b>	<b>CONCLUSIONS AND RECOMMENDATIONS</b>	321
5.1	Conclusions	321
5.2	Recommendations	324
<b>REFERENCES</b>		326

## LIST OF TABLES

Table No.		Page
2.1	Medicinal uses of several <i>Knema</i> species	15
2.2	Flavonoids isolated from the genus <i>Knema</i>	30
2.3	Phenolics isolated from the genus <i>Knema</i>	40
2.4	Anacardic acids isolated from the genus <i>Knema</i>	46
2.5	Acetophenones isolated from the genus <i>Knema</i>	48
2.6	Miscellaneous phytochemicals isolated from the genus <i>Knema</i>	50
2.7	Biological activities of several phytochemicals from the genus <i>Knema</i>	58
3.1	The details of the selected <i>Knema</i> species	76
3.2	The details of the docking coordinates for each protein	108
4.1	The percentage yield and appearance of the essential oils	114
4.2	Chemical components identified from <i>K. intermedia</i> essential oil	117
4.3	Chemical components identified from <i>K. malayana</i> essential oil	120
4.4	Chemical components identified from <i>K. hookeriana</i> essential oil	124
4.5	Chemical components identified from <i>K. furfuracea</i> essential oil	127
4.6	Chemical components identified in the essential oils of four <i>Knema</i> species	130
4.7	NMR data of compound (158)	143
4.8	NMR data of compound (159)	154
4.9	NMR data of compound (160)	160



4.10	NMR data of compound (161)	167
4.11	NMR data of compound (162)	174
4.12	NMR data of compound (163)	181
4.13	NMR data of compound (164)	188
4.14	NMR data of compound (166)	202
4.15	NMR data of compound (167)	209
4.16	NMR data of compound (168)	217
4.17	NMR data of compound (169) and literature	223
4.18	NMR data of compound (170)	231
4.19	NMR data of compound (171)	238
4.20	NMR data of compound (172)	246
4.21	NMR data of compound (173) and literature	253
4.22	NMR data of compound (174)	259
4.23	NMR data of compound (175)	268
4.24	Docking scores of isolated phytochemicals and reference inhibitors	277
4.25	AChE inhibitory activity of the essential oils and crude extracts of <i>Knema</i> species	305
4.26	AChE inhibitory activity of selected phytochemicals of <i>Knema</i> species	308
4.27	LOX inhibitory activity of the essential oils and crude extracts of <i>Knema</i> species	313
4.28	LOX inhibitory activity of selected phytochemicals of <i>Knema</i> species	315
4.29	Antibiofilm activity of the essential oils, extracts and phytochemical of <i>Knema</i> species	318



## LIST OF FIGURES

Figure No.		Page
2.1	<i>Knema intermedia</i> Warb.	17
2.2	<i>Knema malayana</i> Warb.	18
2.3	<i>Knema hookeriana</i> Warb.	19
2.4	<i>Knema furfuracea</i> Warb.	20
2.5	Visual representation of the process of molecular docking	69
3.1	Flow chart for the purification process of <i>K. intermedia</i> leaves extracts	83
3.2	Flow chart for the purification process of <i>K. malayana</i> leaves extracts	85
3.3	Flow chart for the purification process of <i>K. hookeriana</i> leaves extracts	87
3.4	Flow chart for the purification process of <i>K. furfuracea</i> leaves extracts	89
3.5	3D structure of: (A) human acetylcholinesterase (PDB: 4EY7); (B) 5-lipoxygenase (PDB: 6NCF) and (C) fungal cytochrome enzyme (PDB: 4UYM)	109
3.6	Validation of the docking tool, showcasing a comparison between the redocked binding poses of the native (gray color with stick representation) and the docked pose of Donepezil (gold color with stick representation)	110
4.1	Chromatogram of <i>K. intermedia</i> essential oil	119
4.2	Chromatogram of <i>K. malayana</i> essential oil	122
4.3	Chromatogram of <i>K. hookeriana</i> essential oil	123
4.4	Chromatogram of <i>K. furfuracea</i> essential oil	126
4.5	PCA analysis of <i>Knema</i> essential oils	137

4.6	HCA analysis of <i>Knema</i> essential oils	139
4.7A	IR spectrum of compound (158)	144
4.7B	<sup>1</sup> H NMR spectrum of compound (158)	144
4.7C	COSY spectrum of compound (158)	145
4.7D	<sup>13</sup> C NMR spectrum of compound (158)	145
4.7E	DEPT-135 spectrum of compound (158)	146
4.7F	HMQC spectrum of compound (158)	148
4.7G	HMBC spectrum of compound (158)	148
4.7H	NOESY spectrum of compound (158)	149
4.7I	ECD spectrum of compound (158)	149
4.7J	HR-EIMS spectrum of compound (158)	151
4.8A	IR spectrum of compound (159)	155
4.8B	<sup>1</sup> H NMR spectrum of compound (159)	155
4.8C	<sup>13</sup> C NMR spectrum of compound (159)	156
4.8D	EIMS spectrum of compound (159)	156
4.8E	HMQC spectrum of compound (159)	157
4.9A	<sup>1</sup> H NMR spectrum of compound (160)	161
4.9B	COSY spectrum of compound (160)	161
4.9C	<sup>13</sup> C NMR spectrum of compound (160)	162
4.9D	HMQC spectrum of compound (160)	162
4.9E	HMBC spectrum of compound (160)	163
4.10A	<sup>1</sup> H NMR spectrum of compound (161)	165
4.10B	COSY spectrum of compound (161)	165
4.10C	<sup>13</sup> C NMR spectrum of compound (161)	169



4.10D	HSQC spectrum of compound (161)	169
4.10E	HR-EIMS spectrum of compound (161)	170
4.11A	IR spectrum of compound (162)	172
4.11B	<sup>1</sup> H NMR spectrum of compound (162)	172
4.11C	COSY spectrum of compound (162)	173
4.11D	<sup>13</sup> C NMR spectrum of compound (162)	175
4.11E	EIMS spectrum of compound (162)	176
4.11F	HMQC spectrum of compound (162)	178
4.11G	HMBC spectrum of compound (162)	178
4.12A	IR spectrum of compound (163)	180
4.12B	<sup>1</sup> H NMR spectrum of compound (163)	182
4.12C	COSY spectrum of compound (163)	182
4.12D	<sup>13</sup> C NMR spectrum of compound (163)	183
4.12E	HSQC spectrum of compound (163)	184
4.12F	HMBC spectrum of compound (163)	184
4.12G	HR-EIMS spectrum of compound (163)	185
4.13A	IR spectrum of compound (164)	189
4.13B	<sup>1</sup> H NMR spectrum of compound (164)	189
4.13C	COSY spectrum of compound (164)	190
4.13D	APT NMR spectrum of compound (164)	190
4.13E	HMQC spectrum of compound (164)	192
4.13F	HMBC spectrum of compound (164)	192
4.13G	HR-EIMS spectrum of compound (164)	193
4.14A	The ORTEP diagram, drawn at a 50% probability level	195





4.14B	Packing viewed along A-axis (A) and B-axis (B)	197
4.14C	$^1\text{H}$ NMR spectrum of compound (165)	198
4.14D	HR-EIMS spectrum of compound (165)	198
4.15A	IR spectrum of compound (166)	200
4.15B	$^1\text{H}$ NMR spectrum of compound (166)	200
4.15C	COSY spectrum of compound (166)	201
4.15D	APT NMR spectrum of compound (166)	203
4.15E	HMQC spectrum of compound (166)	203
4.15F	HMBC spectrum of compound (166)	204
4.15G	HR-EIMS spectrum of compound (166)	205
4.16A	IR spectrum of compound (167)	207
4.16B	$^1\text{H}$ NMR spectrum of compound (167)	207
4.16C	APT NMR spectrum of compound (167)	211
4.16D	HMQC spectrum of compound (167)	211
4.16E	HR-EIMS spectrum of compound (167)	212
4.17A	$^1\text{H}$ NMR spectrum of compound (168)	215
4.17B	$^{13}\text{C}$ NMR spectrum of compound (168)	215
4.17C	DEPT spectra of compound (168)	216
4.17D	HR-EIMS spectrum of compound (168)	218
4.17E	HMQC spectrum of compound (168)	219
4.18A	IR spectrum of compound (169)	221
4.18B	$^1\text{H}$ NMR spectrum of compound (169)	221
4.18C	$^{13}\text{C}$ NMR spectrum of compound (169)	222
4.18D	GC-MS spectrum of compound (169)	225





4.19A	The ORTEP diagram, drawn at a 50% probability level	228
4.19B	Packing viewed along A-axis (A) and B-axis (B)	229
4.19C	$^1\text{H}$ NMR spectrum of compound (170)	232
4.19D	COSY spectrum of compound (170)	232
4.19E	$^{13}\text{C}$ NMR spectrum of compound (170)	233
4.19F	DEPT spectra of compound (170)	233
4.19G	HMQC spectrum of compound (170)	234
4.19H	HMBC spectrum of compound (170)	235
4.19I	HR-EIMS spectrum of compound (170)	235
4.20A	$^1\text{H}$ NMR spectrum of compound (171)	240
4.20B	$^{13}\text{C}$ NMR spectrum of compound (171)	240
4.20C	HMQC spectrum of compound (171)	242
4.20D	HMBC spectrum of compound (171)	242
4.20E	HR-EIMS spectrum of compound (171)	243
4.21A	IR spectrum of compound (172)	247
4.21B	$^1\text{H}$ NMR spectrum of compound (172)	247
4.21C	COSY spectrum of compound (172)	248
4.21D	$^{13}\text{C}$ NMR spectrum of compound (172)	248
4.21E	DEPT spectra of compound (172)	249
4.21F	HMQC spectrum of compound (172)	249
4.21G	HMBC spectrum of compound (172)	250
4.21H	HR-EIMS spectrum of compound (172)	250
4.22A	IR spectrum of compound (173)	252
4.22B	$^1\text{H}$ NMR spectrum of compound (173)	254



4.22C	$^{13}\text{C}$ NMR spectrum of compound (172)	254
4.22D	DEPT spectra of compound (173)	255
4.22E	HR-EIMS spectrum of compound (173)	255
4.23A	IR spectrum of compound (174)	260
4.23B	$^1\text{H}$ NMR spectrum of compound (174)	260
4.23C	COSY spectrum of compound (174)	261
4.23D	$^{13}\text{C}$ NMR spectrum of compound (174)	261
4.23E	HSQC spectrum of compound (174)	263
4.23F	HMBC spectrum of compound (174)	263
4.23G	EIMS spectrum of compound (174)	264
4.24A	IR spectrum of compound (175)	267
4.24B	$^1\text{H}$ NMR spectrum of compound (175)	270
4.24C	COSY spectrum of compound (175)	270
4.24D	$^{13}\text{C}$ NMR spectrum of compound (175)	271
4.24E	HSQC spectrum of compound (175)	271
4.24F	HMBC spectrum of compound (175)	272
4.24G	HR-EIMS spectrum of compound (175)	273
4.25A	Intermedianin (158) interaction with AChE	279
4.25B	Aptosimon (170) interaction with AChE	271
4.25C	Cubebin (159) interaction with AChE	282
4.25D	3',4',5',5,7-Pentamethoxyflavone (165) interaction with AChE	283
4.26A	Aptosimon (170) interaction with 5-LOX	285
4.26B	Intermedianin (158) interaction with 5-LOX	286
4.26C	Bicubebin A (171) interaction with 5-LOX	287

4.27A	Aptosimon (170) interaction with CYP51	290
4.27B	Intermedianin (158) interaction with CYP51	291
4.28A	Intermedianin (158) oral bioavailability radar	295
4.28B	Cubebin (159) oral bioavailability radar	296
4.28C	Aptosimon (170) oral bioavailability radar	298
4.28D	3',4',5',5',7-Pentamethoxyflavone (165) oral bioavailability radar	299
4.29	Heatmap of the genotoxicity/carcinogenicity prediction results. The color bar represents the risk score values, with 0 (light red) indicating the lowest risk and 1 (dark red) representing the highest risk. The compounds are ranked according to their carcinogenicity risk scores (Risk score Carcino), progressing from the least promising to the most promising	301
4.30	Percentage inhibition of AChE inhibitory activity of <i>Knema</i> essential oils (A) and crude extracts (B) at different concentrations	304
4.31	Percentage inhibition of AChE inhibitory activity of selected <i>Knema</i> phytochemicals at different concentrations	308
4.32	Percentage inhibition of LOX inhibitory activity of <i>Knema</i> essential oils (A) and crude extracts (B) at different concentrations	312
4.33	Percentage inhibition of LOX inhibitory activity of selected <i>Knema</i> phytochemicals at different concentrations	315

## LIST OF SCHEMES

<b>Scheme No.</b>		<b>Page</b>
4.1	Mass fragmentation pattern of compound (158)	150
4.2	Mass fragmentation pattern of compound (162)	176

## LIST OF ABBREVIATIONS

$\alpha$	Alpha
Abs	Absorbance
AChE	Acetylcholinesterase
$\beta$	Beta
$^{13}\text{C}$	Carbon-13
CC	Column Chromatography
$\text{CDCl}_3$	Deuterated chloroform
$\text{CHCl}_3$	Chloroform
$\text{cm}^{-1}$	Reciprocal centimetre
COSY	Correlation spectroscopy
CYP51	Cytochrome P450 51
1D	1 Dimension
2D	2 Dimension
$\delta$	Chemical shift
d	doublet
DCM	Dichloromethane
dd	doublet of doublets
DEPT	Distortionless Enhancement by Polarization Transfer
EIMS	Electron Impact Mass Spectrometry
$\text{Et}_2\text{O}$	Diethyl ether
EtOAc	Ethyl acetate



GC	Gas Chromatography
GC-MS	Gas Chromatography-Mass Spectrometry
GC-FID	Gas Chromatography-Flame Ionisation Detector
$^1\text{H}$	Proton
HMBC	Heteronuclear Multiple Bond Correlation
HMQC	Heteronuclear Multiple Quantum Coherence
HPLC	High Performance Liquid Chromatography
HR-ESIMS	High Resolution Electron Spray Ionisation Mass Spectrometry
Hz	Hertz
IR	Infrared
<i>J</i>	Coupling constant
KBr	Potassium bromide
KI	Kovats Index
L	Liter
LOX	Lipoxygenase
m	multiplet
$\text{M}^+$	Molecular ion
MeOH	Methanol
MHz	Megahertz
min	Minute(s)
<i>m/z</i>	Mass to charge ion
mg	milligram
$\text{MgSO}_4$	Magnesium sulphate
mL	milliliter



mm	millimeter
MS	Mass Spectrometer
NaCl	Sodium chloride
NMR	Nuclear Magnetic Resonance
nm	nanometer
s	singlet
SiO <sub>2</sub>	Silica gel
t	triplet
TLC	Thin Layer Chromatography
PTLC	Preparative Thin Layer Chromatography
VOR	Voriconazole

## CHAPTER 1

### INTRODUCTION



05-4506832

#### 1.1 General Introduction

Perpustakaan Tuanku Bainun  
Kampus Sultan Abdul Jalil Shah

PustakaTBainun



ptbupsi

Natural products are bioactive compounds derived from plants, animals, or microbes. They have long been integral to medicine, food, and cosmetics. Iconic examples such as aspirin (from willow bark) and cannabidiol (from cannabis) underscore their medical importance (Li et al., 2022; O'Reilly et al., 2022). These compounds are often perceived as safer and more sustainable than synthetic drugs, although they are not without risks (Custodio et al., 2022). Despite occasional toxicity or allergenicity, natural products remain in high demand due to their renewability and lower environmental impact. In recent years, technological advances in high-throughput screening, metabolomics, and molecular docking have revolutionized natural product research (Pasdaran et al., 2024), accelerating drug discovery from natural sources, particularly in biodiversity-rich regions such as Malaysia.



05-4506832



pustaka.upsi.edu.my

Perpustakaan Tuanku Bainun  
Kampus Sultan Abdul Jalil Shah

PustakaTBainun



ptbupsi



The study of natural products is particularly significant in biodiversity-rich regions like Malaysia, where the tropical rainforests and marine ecosystems harbor untapped resources. These environments are a treasure trove of chemical diversity, yet many potential compounds remain unexplored. Advances in technology, including high-throughput screening, metabolomics, and molecular docking, are accelerating the discovery and development of natural product-based drugs. However, challenges such as sustainable sourcing, complex compound isolation, and the need for extensive clinical trials must be addressed to fully harness their potential (Pasdaran et al., 2024).

Medicinal plants are utilized in traditional medicine to treat or prevent illnesses and diseases. Cultures worldwide have relied on these plants for thousands of years, and many modern medicines continue to be derived from plant compounds. Medicinal plants contain active compounds with specific properties, such as anti-inflammatory, antioxidant, or antimicrobial effects, which make them effective for treating various conditions. In recent years, the popularity of medicinal plants has increased as people seek natural remedies and alternatives to pharmaceutical drugs. Notably, many pharmaceutical medications are derived from plant compounds, including morphine from the opium poppy and taxol from the Pacific yew tree. The use of medicinal plants and their applications is likely to continue gaining traction in the future (Hamedi et al., 2022).

Malaysia is renowned for its rich biodiversity and traditional use of medicinal plants, which play a significant role in the healthcare practices of its multicultural society. The country's rainforests are home to numerous endemic species that have been used for centuries in traditional Malay, Chinese, and Indian medicine. These





plants are integral to practices like Malay jamu, Traditional Chinese Medicine (TCM), and Ayurveda, addressing ailments ranging from minor infections to chronic diseases. Many medicinal plants from Malaysia have been scientifically studied, revealing promising pharmacological properties and potential for modern drug development (Tan et al., 2023).

Among the most notable medicinal plants is *Eurycoma longifolia*, commonly known as Tongkat Ali, traditionally used as an energy enhancer and aphrodisiac. It contains bioactive compounds like quassinoids and alkaloids, exhibiting antioxidant and anti-malarial properties. Another widely recognized plant is *Labisia pumila*, or Kacip Fatimah, valued for its role in women's health, particularly in postpartum care and hormonal balance, due to its rich content of flavonoids and saponins. *Orthosiphon stamineus*, or Misai Kucing, is another popular herb used to promote urinary tract health, thanks to its diuretic and anti-inflammatory effects. Similarly, *Centella asiatica*, locally known as Pegaga, is prized for its wound-healing and neuroprotective properties, attributed to its triterpenoids like asiaticoside. Other examples include the Bitter Gourd (*Momordica charantia*), known for its hypoglycemic effects in managing diabetes, and Temu Lawak (*Curcuma xanthorrhiza*), which supports digestion and liver health (Nasir et al., 2015).

Despite the immense potential of these plants, challenges such as overharvesting, lack of standardization in herbal products, and limited clinical studies persist. Sustainable harvesting practices, preservation of traditional knowledge, and rigorous research are crucial to unlocking the full potential of Malaysia's medicinal plants. With proper conservation and scientific validation, these natural resources





could significantly contribute to global healthcare and pharmaceutical development while preserving Malaysia's cultural heritage.

Plants from the Myristicaceae family hold a prominent place in traditional medicine due to their extensive therapeutic applications. The significance of Myristicaceae in natural products research and traditional medicine is well-documented, showcasing its dual role as a source of both traditional remedies and novel drug discovery leads. Indigenous knowledge about these plants reflects a deep understanding of their medicinal potential, passed down through generations. This traditional use underscores the broader importance of natural products in healthcare, serving as the foundation for many traditional healing systems globally, including Malaysia's (Barman et al., 2021).



Moreover, the therapeutic benefits of Myristicaceae plants highlight the essential role of natural products in bridging traditional practices with modern pharmacology. Shahidan et al. (2022) emphasize the need for further exploration and preservation of this indigenous knowledge, as it offers insights into sustainable healthcare solutions and new opportunities for developing plant-based pharmaceuticals. This integration of traditional wisdom and scientific validation continues to demonstrate the enduring relevance of natural products in addressing both historical and contemporary health challenges.





## 1.2 Problem Statement

The discovery of an alternative treatment method using plant-based traditional medicine has emerged due to the various adverse effects associated with modern drug-based therapies commonly used today. Several *Knema* species are used medicinally, with the seeds and bark traditionally employed to treat skin disorders, mouth and throat sores, cancer, wounds, acne, and rheumatism. Additionally, some *Knema* species are utilized to address conditions such as jaundice, chronic fever, inflammation, spleen disorders, respiratory issues, and impaired taste sensation. Moreover, these plants are reportedly used in traditional Thai medicine as a whole-body tonic, blood tonic, and anticancer agent (Chuakul et al., 2004; Salleh & Ahmad, 2017; Supriya & Sreekanth, 2021).



Although plants in the Myristicaceae family have attracted considerable research attention for the isolation and identification of phytochemicals, the genus *Knema* remains largely unexplored in this regard. Additionally, limited research has been conducted on the essential oils of species within this genus. To the best of our knowledge, no studies have reported on the essential oils of the selected *Knema* species in this study; *K. intermedia*, *K. malayana*, *K. hookeriana*, and *K. furfuracea*. Moreover, phytochemical investigations of these species are scarce, with the exception of *K. hookeriana* (Geny et al., 2016; Alen et al., 2000). Given these gaps and the reported traditional and ethnobotanical uses, there is a clear motivation to identify the active compounds responsible for the biological activities.



Therefore, we aim to isolate and characterize the biologically active compounds present in these four species, as well as to perform computational studies to understand how these compounds exert therapeutic effects in the human body. This will include predicting interactions between drugs and proteins and analyzing their impact on biological pathways and functions

### 1.3 Objectives of Study

The objectives of the study are:

1. To investigate the chemical compositions of the essential oils from the leaves of four *Knema* species (*K. intermedia*, *K. malayana*, *K. hookeriana*, and *K. furfuracea*).
2. To isolate the phytochemicals from the leaves extract of four *Knema* species (*K. intermedia*, *K. malayana*, *K. hookeriana*, and *K. furfuracea*) and characterize spectroscopically (IR, NMR, UV, and MS).
3. To perform the computational studies on the isolated phytochemicals using molecular docking and drug-likeness (ADMET).
4. To determine the biological activities (acetylcholinesterase, anti-inflammatory, and antibiofilm) of the essential oils, crude extracts, and selected phytochemicals.

## 1.4 Scopes of Study

The study was divided into four parts. The first part focused on the extraction of essential oils from the leaves of *K. intermedia*, *K. malayana*, *K. hookeriana* and *K. furfuracea* using the hydrodistillation method. The chemical compositions of the essential oils were analyzed using gas chromatography (GC-FID), gas chromatography-mass spectrometry (GC-MS), and Kovats indices.

The second part involved the extraction, isolation, purification, and characterization of phytochemicals from the dried leaves of *Knema* species. The cold extraction method was employed with solvents of varying polarities. The crude extracts were fractionated using vacuum liquid chromatography (VLC), followed by purification of the fractions through gravity column chromatography (CC) and preparative thin-layer chromatography (TLC) to obtain pure phytochemicals. Characterization of the isolated compounds was conducted using various spectroscopic methods, including infrared (IR), ultraviolet (UV), one-dimensional and two-dimensional nuclear magnetic resonance (NMR), and mass spectrometry (MS).

The third part comprised computational studies, which included molecular docking and drug-likeness (ADMET) prediction. These studies aimed to predict the most active phytochemicals and elucidate their interactions with target enzymes (proteins), providing critical insights for selecting phytochemicals for *in vitro* assays.

Finally, the biological activities, including acetylcholinesterase inhibition, anti-inflammatory effects, and fungal antibiofilm activity, were assessed for the essential

oils, crude extracts, and selected phytochemicals. Acetylcholinesterase activity was measured using the electric eel (*Electrophorus electricus*) with acetylthiocholine iodide as the substrate. Anti-inflammatory activity was evaluated against the lipoxygenase enzyme, while antibiofilm activity was tested using crystal violet assay against *Candida* species.

### 1.5 Significance of Study

The significance of this study lies in its pioneering and comprehensive investigation of the phytochemical composition of *K. malayana*, *K. intermedia*, *K. hookeriana* and *K. furfuracea*. This research is the first to explore the chemical constituents of *K. malayana* and *K. intermedia*, with the aim of isolating and identifying novel bioactive compounds from these species. The discovery of new compounds is crucial, as they may exhibit unique pharmacological properties with potential therapeutic applications. Despite the traditional medicinal use of these *Knema* species in Southeast Asia, scientific validation of their bioactive compounds and medicinal properties has been limited. This study addresses that gap by identifying bioactive compounds and evaluating their biological activities, thereby contributing to the growing body of knowledge on the genus *Knema*.

The discovery of new compounds from these species could significantly advance the development of treatments for inflammatory conditions, fungal infections, and microbial infections. Furthermore, this research has broader implications for drug discovery and the pharmaceutical industry's natural product-based medicines. In



addition to its pharmacological contributions, the study emphasizes the importance of preserving Malaysia's rich biodiversity by highlighting the medicinal potential of *Knema* species, which contributes to the conservation of natural resources for future generations. Through this pioneering investigation of *K. malayana* and *K. intermedia*, the study provides valuable insights into the chemical, enzymatic, and medicinal profiles of these plants.

